Acneiform Eruptions
Severe 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) intoxication: clinical and laboratory effects. (1/20)
A variety of health effects have been attributed to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), but little information is available on the course of a verified high-level TCDD intoxication. In this paper we describe two cases of heavy intoxication with TCDD and present a 2-year follow-up including clinical, biochemical, hematologic, endocrine, and immunologic parameters monitored in two women, 30 and 27 years of age, who suffered from chloracne due to TCDD intoxication of unknown origin. Patient 1, who had the highest TCDD level ever recorded in an individual (144,000 pg/g blood fat), developed severe generalized chloracne, whereas in the second patient, despite heavy intoxication (26,000 pg/g blood fat), only mild facial acne lesions occurred. Both patients initially experienced nonspecific gastrointestinal symptoms. In Patient 1 we observed a moderate elevation of blood lipids, leukocytosis, anemia, and secondary amenorrhoea. The laboratory parameters in Patient 2 were all normal. Despite the high TCDD levels, apart from chloracne, only few clinical and biochemical health effects were observed within the first 2 years after TCDD intoxication. (+info)Papulopustular skin lesions are seen more frequently in patients with Behcet's syndrome who have arthritis: a controlled and masked study. (2/20)
OBJECTIVE: To determine the prevalence of acneiform skin lesions (comedones, papules, and pustules) in patients with Behcet's syndrome (BS) with arthritis. METHODS: Study groups included 44 patients with BS with arthritis (32 men, 12 women, mean (SD) age 37.8 (8.9)), 42 patients with BS without arthritis (31 men, 11 women, mean age 35.5 (6.4)), 21 patients with active rheumatoid arthritis (five men, 16 women, mean age 48.8 (14)), and 33 healthy volunteers (28 men, five women, mean age 40.1 (8.1)). All probands and controls were examined by a rheumatologist and a dermatologist, in a prospective and masked protocol. An ophthalmological evaluation was performed if necessary. Skin lesions, including comedones, papules, and pustules, were counted and scored as 0: absent, 1: 1-5, 2: 6-10, 3: 11-15, 4: 16-20, and 5: >20. RESULTS: Although there was no significant difference between the four groups in the prevalence of comedones, the number of papules and pustules was significantly higher in patients with BS with arthritis (p=0.0037 for papules and p<0.0001 for pustules) than in the remaining three groups. CONCLUSION: Acneiform skin lesions (papules and pustules) seem to be more frequent in patients with BS with arthritis. This suggest that the arthritis seen in BS may possibly be related to acne associated arthritis. (+info)Acneiform facial eruptions: a problem for young women. (3/20)
OBJECTIVE: To summarize clinical recognition and current management strategies for four types of acneiform facial eruptions common in young women: acne vulgaris, rosacea, folliculitis, and perioral dermatitis. QUALITY OF EVIDENCE: Many randomized controlled trials (level I evidence) have studied treatments for acne vulgaris over the years. Treatment recommendations for rosacea, folliculitis, and perioral dermatitis are based predominantly on comparison and open-label studies (level II evidence) as well as expert opinion and consensus statements (level III evidence). MAIN MESSAGE: Young women with acneiform facial eruptions often present in primary care. Differentiating between morphologically similar conditions is often difficult. Accurate diagnosis is important because treatment approaches are different for each disease. CONCLUSION: Careful visual assessment with an appreciation for subtle morphologic differences and associated clinical factors will help with diagnosis of these common acneiform facial eruptions and lead to appropriate management. (+info)Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. (4/20)
BACKGROUND: Radiation dermatitis occurs to some degree in most patients receiving radiotherapy, with or without chemotherapy. Patients with squamous cell carcinoma of the head and neck (SCCHN) who receive radiotherapy in combination with epidermal growth factor receptor (EGFR) inhibitors, such as cetuximab, may develop a characteristic acne-like rash in addition to dermatitis. DESIGN: An advisory board of 11 experienced radiation oncologists, medical oncologists and dermatologists discussed the management options for skin reactions in patients receiving EGFR inhibitors and radiotherapy for SCCHN. Skin toxicity was categorised according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (version 3) grading. RESULTS: Both general and grade-specific approaches for the management of dermatitis in this patient group are presented. It was concluded that where EGFR inhibitor-related acne-like rash and dermatitis coexist within irradiated fields, management should be based on the grade of dermatitis: for grade 1 (or no dermatitis), treatment recommendations for EGFR-related acne-like rash outside irradiated fields should be followed; for grades 2 and above, treatment recommendations for dermatitis were proposed. CONCLUSIONS: This paper presents comprehensive consensus guidelines for the treatment of dermatitis in patients with SCCHN receiving EGFR inhibitors in combination with radiotherapy. (+info)Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatment. (5/20)
BACKGROUND: Skin toxicity is a common adverse effect of erlotinib and other anti-epidermal growth factor receptor (EGFR) agents. The aim of the study was to explore the relationship between markers in the EGFR pathway and skin rash. PATIENTS AND METHODS: Eighteen patients with metastatic breast cancer were treated with daily oral erlotinib at 150 mg. Skin biopsies were obtained at baseline and after 1 month of treatment in 15 patients. EGFR, phosphorylated EGFR (pEGFR), phosphorylated mitogen-activated protein kinase (pMAPK), and phosphorylated Akt (pAkt) or Ki67 were examined quantitatively by immunohistochemistry. RESULTS: 11 of 18 (61%, 95% confidence interval 35.7% to 82.7%) patients developed skin rash. pAkt at baseline was significantly higher in patients with no rash than those with a grade 1 or 2 rash (18.8 +/- 8.3 versus 2.4 +/- 1.2 versus 3.3 +/- 3.3; P = 0.0017 for trend). There was a trend towards a significant increase of pMAPK in skin posttreatment with increasing grade of rash (no rash versus grade 1 versus grade 2 rash: 4.5 +/- 2.3 versus 8.4 +/- 4.2 versus 19.4 +/- 4.6; P = 0.036). Other markers were not associated with rash. CONCLUSIONS: pAkt was significantly associated with not developing a rash and may have a predictive utility for skin toxicity in patients treated with erlotinib and possibly with other anti-EGFR agents. (+info)Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. (6/20)
PURPOSE: To evaluate the ability of either oral minocycline, topical tazarotene or both, to reduce or prevent cetuximab-related acneiform rash when administered starting on day 1 of cetuximab therapy. PATIENTS AND METHODS: Metastatic colorectal cancer patients preparing to initiate cetuximab were randomly assigned to receive daily oral minocycline or placebo, and to receive topical tazarotene application to either left or right side of the face. Both therapies were administered for 8 weeks. RESULTS: Forty-eight eligible patients were randomly assigned to minocycline (n = 24) or placebo (n = 24). Total facial lesion counts were significantly lower in patients receiving minocycline at weeks 1 through 4. At week 4, a lower proportion of patients in the minocycline arm reported moderate to severe itch than in the placebo arm (20% v 50%, P = .05). Facial photographs, obtained at week 4, were reviewed for rash global severity. Patients in the minocycline arm trended toward lower frequency of moderate to severe rash than patients receiving placebo (20% v 42%, P = .13). The differences in total facial lesion counts and subjectively assessed itch were diminished by week 8. Cetuximab treatment was interrupted because of grade 3 skin rash in four patients in the placebo arm, and none in the minocycline arm. There was no observed clinical benefit to tazarotene application. Tazarotene treatment was associated with significant irritation, causing its discontinuation in one third of patients. CONCLUSION: Prophylaxis with oral minocycline may be useful in decreasing the severity of the acneiform rash during the first month of cetuximab treatment. Topical tazarotene is not recommended for management of cetuximab-related rash. (+info)Severe acneiform eruption induced by cetuximab (Erbitux). (7/20)
(+info)Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. (8/20)
(+info)Acneiform eruptions refer to skin conditions that resemble or mimic the appearance of acne vulgaris. These eruptions are characterized by the presence of papules, pustules, and comedones on the skin. However, acneiform eruptions are not true acne and can be caused by various factors such as medications, infections, or underlying medical conditions.
Some examples of acneiform eruptions include:
* Drug-induced acne: Certain medications such as corticosteroids, lithium, and antiepileptic drugs can cause an acne-like rash as a side effect.
* Rosacea: A chronic skin condition that causes redness, flushing, and pimple-like bumps on the face.
* Pseudofolliculitis barbae: A condition that occurs when curly hair grows back into the skin after shaving, causing inflammation and acne-like lesions.
* Gram-negative folliculitis: A bacterial infection that can occur as a complication of long-term antibiotic use for acne treatment.
It is important to distinguish acneiform eruptions from true acne vulgaris, as the treatment approach may differ depending on the underlying cause. Dermatologists or healthcare providers specializing in skin conditions can provide an accurate diagnosis and recommend appropriate treatment options.
Tooth eruption is the process by which a tooth emerges from the gums and becomes visible in the oral cavity. It is a normal part of dental development that occurs in a predictable sequence and timeframe. Primary or deciduous teeth, also known as baby teeth, begin to erupt around 6 months of age and continue to emerge until approximately 2-3 years of age. Permanent or adult teeth start to erupt around 6 years of age and can continue to emerge until the early twenties.
The process of tooth eruption involves several stages, including the formation of the tooth within the jawbone, the movement of the tooth through the bone and surrounding tissues, and the final emergence of the tooth into the mouth. Proper tooth eruption is essential for normal oral function, including chewing, speaking, and smiling. Any abnormalities in the tooth eruption process, such as delayed or premature eruption, can indicate underlying dental or medical conditions that require further evaluation and treatment.
Acneiform eruption
Childhood granulomatous periorificial dermatitis
Acne
Acne (disambiguation)
Neonatal acne
Metronidazole
Amineptine
Acne fulminans
List of skin conditions
Infantile acne
Pomade acne
Halogen acne
Acne medicamentosa
Granulomatous facial dermatitis
Rhinophyma
Eruptive vellus hair cyst
Acne cosmetica
Tar acne
Oil acne
Otophyma
Blepharophyma
Metophyma
Gnathophyma
Dissecting cellulitis of the scalp
Lupus miliaris disseminatus faciei
Gram-negative rosacea
Acne with facial edema
Occupational acne
Idiopathic facial aseptic granuloma
Excoriated acne
Acneiform eruption - Wikipedia
Acneiform Eruptions: Practice Essentials
Severe EGFR inhibitor-induced acneiform eruption responding to dapsone
Acneiform Eruptions | Profiles RNS
PubMed RSS Feed - - Morphology-Based Diagnosis of Acneiform Eruptions. - RSS - RRDi Member Forum
Novel Triple Threat Approach to Acne Beats Placebo
A case of acneiform skin eruption associated with ZD1839(Iressa®) - Fingerprint - Korea University
Anusol Hc (Hydrocortisone Cream): Uses, Dosage, Side Effects, Interactions, Warning
Dermasorb TA: Package Insert - Drugs.com
Pseudofolliculitis of the Beard: Background, Pathophysiology, Etiology
DailyMed - DESOXIMETASONE ointment
What to know about laser skin tightening | Medical News Today
Positive Health Online | Article - Natural Treatment Options for Acne Vulgaris
Pediatric Contact Dermatitis: Practice Essentials, Background, Pathophysiology
Advanced Search Results - Public Health Image Library(PHIL)
Seysara (sarecycline) dosing, indications, interactions, adverse effects, and more
Buy Alcortin a Gel Online at Competitive Price
Acnomel, Acnotex (resorcinol/sulfur) dosing, indications, interactions, adverse effects, and more
Nontuberculous Mycobacterial Infection after Fractionated CO2 Laser Resurfacing - Volume 19, Number 3-March 2013 - Emerging...
SciELO - Brazil - Pyodermitis Pyodermitis
2004 - Gorgas Course | UAB
Steroid acne | DermNet
Catherine Smith - Research output - King's College London
Medical Dictionary, Dictionary of medicine and human biology, medical, biological and chemical terminology
Incidence of Adverse Cutaneous Reactions to Epidermal Growth Factor Receptor Inhibitors in Patients with Non-Small-Cell Lung...
Answers to Dermatophile questions | ADC Education & Practice Edition
Can Topical Hydrocortisone Help with Acne? - Acne.org
Nemasole 100 mg - Proven Nemasole no RX
Folliculitis1
- Classically described as an acneiform eruption, Malassezia folliculitis appears as 1- to 2-mm, erythematous, monomorphic, pruritic papules and pustules on the upper trunk, neck, and upper arms, and less frequently on the face. (contemporarypediatrics.com)
Acne8
- Acneiform eruptions, or acne mimicking eruptions, are a group of skin conditions characterized by small bumps resembling acne. (wikipedia.org)
- Acneiform eruptions are dermatoses that resemble acne vulgaris. (medscape.com)
- While acne vulgaris typically consists of comedones, acneiform eruptions (such as acneiform drug eruptions) usually lack comedones clinically. (medscape.com)
- Acneiform eruptions can be distinguished from acne vulgaris by a history of sudden onset, monotonous lesion morphology, and development of the eruption at an age outside the range typical of acne vulgaris. (medscape.com)
- Distinguishing between true acne vulgaris and the various acneiform eruptions is important yet sometimes challenging. (irosacea.org)
- Given the common nature of acne and acneiform eruptions, the pediatrician must be aware of these lesion patterns and possess the skills to effectively evaluate the pediatric presentation of these eruptions. (irosacea.org)
- This article discusses several of the most common acneiform eruptions, including neonatal acne and cephalic pustulosis, periorificial dermatitis (perioral dermatitis), facial angiofibromas, iatrogenic acneiform drug eruptions, and childhood rosacea. (irosacea.org)
- Acneiform Eruptions in Dermatology is a practical, full-color guide to the differential diagnosis of acne vulgaris and the treatment of acne-like conditions. (nshealth.ca)
Lesions2
- Patients with acneiform eruptions present with acnelike lesions such as papulonodules, pustules, and cysts. (medscape.com)
- Patients with DL present with 10-300 lesions that are a mixture of acneiform, ulcerative, papular, and nodular types. (uab.edu)
Cutaneous toxicity1
- Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib. (medicaljournalssweden.se)
Drug-induced2
- In the case of drug-induced acneiform eruptions, the eruption resolves with discontinuation of the medication. (medscape.com)
- Drug Induced Acneiform Eruptions -- 54. (nshealth.ca)
Secondary3
- Pustular acneiform secondary syphilis. (medscape.com)
- We present a 72-year-old-man with a history of EGFR+ non-small-cell lung carcinoma who developed a severe acneiform eruption secondary to afatinib that failed to improve with various traditional treatment modalities. (cdlib.org)
- This image shows a morbiliform eruption secondary to use of a drug. (msdmanuals.com)
Diseases1
- The workup of acneiform eruptions varies greatly, reflecting the wide variety of diseases. (medscape.com)
Hypersensitivity1
- Hydroquinone is powerful but can owing hypersensitivity and acneiform eruptions. (sahmy.com)
Neonatal1
- Neonatal cephalic pustulosis is an alternate term used to describe this benign neonatal eruption. (dermatologyadvisor.com)
EGFR3
- Oral tetracyclines represent an efficacious prophylactic option for acneiform eruptions due to epidermal growth factor receptor (EGFR) inhibitors. (medscape.com)
- Prevention and management of acneiform rash associated with EGFR inhibitor therapy: A systematic review and meta-analysis. (medscape.com)
- Dapsone can be an effective therapy for refractory or severe cases of EGFR-induced acneiform eruptions. (cdlib.org)
Diagnosis1
- Morphology-Based Diagnosis of Acneiform Eruptions. (irosacea.org)
Papules1
- Infants present with acneiform papules and pustules, frequently located on the cheeks and forehead and sometimes on the chest. (bmj.com)
Inhibitors1
- Bierbrier R, Lam M, Pehr K. A systematic review of oral retinoids for treatment of acneiform eruptions induced by epidermal growth factor receptor inhibitors. (medscape.com)
Patients1
- Occasionally, patch testing can be helpful in patients with fixed drug eruptions. (msdmanuals.com)
Reactions2
- Acnelike eruptions develop as a result of infections, hormonal or metabolic abnormalities, genetic disorders, and drug reactions. (medscape.com)
- Drugs can cause multiple skin eruptions and reactions. (msdmanuals.com)
Rash1
- This photo shows acneiform rash on the chest caused by corticosteroid treatment. (msdmanuals.com)
Corticosteroid1
- Therapy of severe cetuximab-induced acneiform eruptions with oral retinoid, topical antibiotic and topical corticosteroid]. (bvsalud.org)
Therapy1
- The patient was treated with dapsone and his acneiform eruption resolved within two months of initiating therapy. (cdlib.org)
Adverse1
- Cutaneous adverse effects, most commonly acneiform/papulopustular eruption, can occur with these medications and limit their tolerability. (cdlib.org)
Disease1
- Generalized Necrobiotic Palisading Granulomatous Follicular Eruption: A Peculiar Pustular Variant of Perforating Granuloma Annulare or an Individualized Disease? (medscape.com)
Shows1
- This graph shows the total number of publications written about "Acneiform Eruptions" by people in this website by year, and whether "Acneiform Eruptions" was a major or minor topic of these publications. (childrensmercy.org)
Hair1
- Binhlam JQ, Gross AS, Onadeko OO, Dutt PL, King LE Jr. Acneiform eruption due to eruptive vellus hair cysts. (medscape.com)
Generally1
- An acneiform eruption occurring mostly in middle-aged adults and appearing generally on the forehead, cheeks, nose, and chin. (dermis.net)
Cutaneous2
- Cutaneous adverse reactions range from acneiform eruptions to toxic epidermal necrolysis. (nih.gov)
- Toxicities primarily cutaneous, especially papulopustular eruption, described as acneform rashes. (standardofcare.com)
Reactions3
- Acnelike eruptions develop as a result of infections, hormonal or metabolic abnormalities, genetic disorders, and drug reactions. (medscape.com)
- Drugs can cause multiple skin eruptions and reactions. (msdmanuals.com)
- Such reactions can sometimes cause skin problems, including acneiform eruptions. (exposedskincare.com)
Preventing acneiform rash1
- 3. Topical vitamin K1 may not be effective in preventing acneiform rash during cetuximab treatment in patients with metastatic colorectal cancer. (nih.gov)
Dermatoses2
Papulopustular eruption2
- Epidermal growth factor receptor inhibitor papulopustular eruption may be a surrogate marker for the drugs efficacy with a positive correlation between the rash and tumor response, survival or both. (standardofcare.com)
- Skin toxicity is the most common adverse effect associated with EGFR-TKI therapy (approximately 50-80%), which mainly includes acneiform eruption, papulopustular eruption, or pruritus. (biomedcentral.com)
Follicular3
- Generalized Necrobiotic Palisading Granulomatous Follicular Eruption: A Peculiar Pustular Variant of Perforating Granuloma Annulare or an Individualized Disease? (medscape.com)
- Nearly half a century ago, Weary et al reported the case of a 36 year-old woman with an acneiform eruption composed of uniform small follicular papules and pustules, surrounded by a rim of erythema, distributed symmetrically over her upper trunk, abdomen, neck and face. (aad.org)
- Acneiform eruptions , i.e., follicular papules and pustules , may also arise in the scalp. (dermnetnz.org)
Hypertrichosis1
- The well-documented drug-specific skin manifestations include cyclosporine-related hypertrichosis, gingival hypertrophy, steroid-induced acneiform eruption and striae. (annals.edu.sg)
Pustular1
- Pustular acneiform secondary syphilis. (medscape.com)
Epidermal2
- Bierbrier R, Lam M, Pehr K. A systematic review of oral retinoids for treatment of acneiform eruptions induced by epidermal growth factor receptor inhibitors. (medscape.com)
- Choosing between isotretinoin and acitretin for epidermal growth factor receptor inhibitor and small molecule tyrosine kinase inhibitor acneiform eruptions. (mayo.edu)
Pustules2
- Patients with acneiform eruptions present with acnelike lesions such as papulonodules, pustules, and cysts. (medscape.com)
- Acneiform Eruptions occur when the nodes of the pustules are filled with lesion-like substances. (mfine.co)
Clinically1
- Clinically, acneiform eruptions are characteristically monomorphic. (medicoapps.org)
Discontinuation1
- In the case of drug-induced acneiform eruptions, the eruption resolves with discontinuation of the medication. (medscape.com)
Skin1
- In the early stage, skin eruptions were the most prominent features of yusho. (nih.gov)
Symptoms1
- Symptoms mostly include harmful eruptions on the facial region. (mfine.co)
Infections1
- Infections caused by these organisms could lead to acneiform eruptions: Proteus, Klebsiella, Escherichia coli, and Enterobacter. (mfine.co)
Occurs1
- The eruption onset usually occurs within 2-4 weeks of TKI initiation but may also occur earlier or later [ 5 ]. (biomedcentral.com)